Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk. Read more about Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk.
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Read more about A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers. Read more about Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers.
Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Read more about Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Read more about Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.
Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Read more about Tiling path genomic profiling of grade 3 invasive ductal breast cancers.
PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Read more about PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.
Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model. Read more about Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model.
p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803. Read more about p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803.
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Read more about Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.
